NC
DNTH icon

Nexthera Capital’s Dianthus Therapeutics DNTH Stock Holding History

Nexthera Capital’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-9,375
Closed -$1.8M – 31
2018
Q3 		$1.8M Hold
9,375
– – 0.35% 39
2018
Q2 		$2.02M Buy
+9,375
New +$2.12M 0.31% 36

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $139B AUM 29.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
HMC
Harvard Management Company Boston, Massachusetts $4.26B AUM 5.81% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Nexthera Capital's DNTH Position: Q4 2018 in Review

Nexthera Capital sold out of Dianthus Therapeutics (DNTH) in Q4 2018, closing a stake of 9,375 shares — an estimated $1.8M sold.

Nexthera Capital first reported a position in DNTH in Q2 2018 and held it in 2 quarters. The position peaked at $2.02M in Q2 2018. 54 funds tracked by Wall St. Rank hold DNTH as of Q4 2018.

  • Nexthera Capital reported no remaining Dianthus Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Nexthera Capital sold 9,375 Dianthus Therapeutics shares in Q4 2018, an estimated $1.8M.
  • Nexthera Capital first reported a position in Dianthus Therapeutics in Q2 2018 and held it in 2 quarters.
  • Nexthera Capital's Dianthus Therapeutics position peaked at $2.02M in Q2 2018.
  • 54 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2018.

Based on Nexthera Capital's 13F filing for Q4 2018, filed 14 Feb 2019.